Formulação probiótica de Lactobacillus fermentum atenua dislipidemia, inflamação e estresse oxidativo em ratos alimentados com uma dieta hiperlipídica

• Autor(a) principal: Freire, Micaelle Oliveira de Luna
• Data de Publicação: 2021
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
• Texto Completo: https://repositorio.ufpb.br/jspui/handle/123456789/21301
• topic: Dislipidemia; Estresse oxidativo; Inflamação; Microbiota intestinal; Lactobacillus; Probióticos; Dyslipidemia; Oxidative stress; Inflammation; Intestinal microbiota; Probiotics; CNPQ::CIENCIAS BIOLOGICAS::FISIOLOGIA

The imbalance of the intestinal microbiota (IM) induced by a high fat diet has been associated with the development of cardiometabolic disorders. Some studies have demonstrated possible methods for maintaining IM homeostasis, with administration with probiotics being one of the choices for using non-pharmacological intervention. These compounds are known to contribute to the health of the host, through their hypocholesterolemic, anti-inflammatory and antioxidant properties, and can be a promising strategy for the treatment of metabolic and cardiovascular diseases. The present study aimed to investigate the effects of oral administration of a probiotic formulation containing Lactobacillus fermentum 139, 263 and 296 on the biochemical parameters, inflammation and oxidative stress in rats fed a high-fat diet. The rats were divided into three experimental groups: control group (control diet + placebo), HFHC group (diet rich in lipids and cholesterol + placebo), and group HFHC + Lf (diet rich in lipids and cholesterol + L. fermentum 139, 263 and 296). These groups were submitted to supplementation with placebo solution or L. fermentum 139, 263 and 296, for 4 weeks, twice a day. The evaluation of body weight and food consumption occurred throughout the experiment, and after 4 weeks of supplementation, serum, colon and heart tissues and feces were collected to perform: measurement of serum lipid profile and inflammatory cytokines, quantification of acids organics and sugars in animal feces, in addition to evaluation of malondialdehyde (MDA) and activity of antioxidant enzymes and total thiol groups in colon and heart tissues. The results of the present study demonstrated that supplementation improved body weight and food consumption when compared to the HFHC group. The HFHC-Lf group showed a reduction in serum levels of total cholesterol (TC), low-density lipoprotein (LDL) and triglycerides (TG), and a reduction in high-density lipoprotein (HDL), in addition to reducing atherogenic indices when compared to dyslipidemic group. Administration with L. fermentum 139, 263 and 296 reduced IL-1β and increased IL-10. The administration with L. fermentum 139, 263 and 296 contributed to the increase in raffinose in the feces, but without significant changes in fructose and short-chain fatty acids. In addition, supplementation with L. fermentum 139, 263 and 296 was able to reduce MDA concentrations and increase superoxide dismutase (SOD), glutathione-S-transferase (GST) and total thiol groups in the colon, and promote increased catalase activity (CAT), GST and amount of total thiol groups in cardiac tissues. Therefore, these results indicate the potential effects promoted by L. fermentum 139, 263 and 296 on biochemical parameters, in addition to the anti-inflammatory and antioxidant properties of these probiotic strains, which can be used as possible therapeutic agents in cardiometabolic disorders.